Cargando…

Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops

Purpose. To compare the ocular pulse amplitude (OPA) lowering effects of preservative-free tafluprost and dorzolamide-timolol fixed combination (DTFC) using dynamic contour tonometry. Methods. In total, 66 eyes of 66 patients with normal tension glaucoma (NTG) (n = 34) or primary open angle glaucoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Du Ri, Ha, Seung Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628750/ https://www.ncbi.nlm.nih.gov/pubmed/26557671 http://dx.doi.org/10.1155/2015/435874

Ejemplares similares

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2016)

Correction to: 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2020)

Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free COSOPT(®)) in patients with open-angle glaucoma or ocular hypertension
por: Hutnik, Cindy, et al.
Publicado: (2010)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
por: Park, Sang-Woo, et al.
Publicado: (2022)

Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/timolol
por: Kwon, Junki, et al.
Publicado: (2015)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
por: Kim, Joon Mo, et al.
Publicado: (2021)

Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes
por: Ansari, E., et al.
Publicado: (2022)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy
por: Oddone, Francesco, et al.
Publicado: (2022)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
por: Ansari, Ejaz, et al.
Publicado: (2021)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
por: Garcia-Medina, Jose J., et al.
Publicado: (2022)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
por: Tokuda, Naoto, et al.
Publicado: (2017)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat, Lutz E, et al.
Publicado: (2017)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl, Ines, et al.
Publicado: (2013)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate, Ngamkae, et al.
Publicado: (2020)

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components
por: Pfeiffer, Norbert, et al.
Publicado: (2014)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş, Sıtkı Samet
Publicado: (2012)

Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
por: So, Ha-Rim, et al.
Publicado: (2020)

Switching from concomitant therapy to tafluprost/timolol fixed combination
por: Inoue, Kenji, et al.
Publicado: (2018)

Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
por: Fuwa, Masahiro, et al.
Publicado: (2019)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer, Anton, et al.
Publicado: (2011)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau, Ana, et al.
Publicado: (2013)

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
por: Fuwa, Masahiro, et al.
Publicado: (2016)

Allergic contact dermatitis caused by dorzolamide eyedrops
por: Lee, Seung-Jun, et al.
Publicado: (2015)

Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops
por: Safarzadeh, Masoud, et al.
Publicado: (2017)

Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study
por: Galose, Mary S, et al.
Publicado: (2016)

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
por: Holló, Gábor, et al.
Publicado: (2014)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Teus, Miguel A, et al.
Publicado: (2009)

A patient preference comparison of Azarga(™) (brinzolamide/timolol fixed combination) vs Cosopt(®) (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Mundorf, Thomas K, et al.
Publicado: (2008)

Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2018)

A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
por: Gómez-Aguayo, Francisco, et al.
Publicado: (2018)

Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future
por: Konstas, Anastasios G., et al.
Publicado: (2020)

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study
por: Rolle, Teresa, et al.
Publicado: (2017)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi, Hideaki, et al.
Publicado: (2017)

Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension
por: Ichhpujani, Parul, et al.
Publicado: (2010)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
por: Hwang, Young Hoon
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gal4n61qo53jcl558me6h9f431